



(10) International Publication Number
WO 2016/020856 A2


(43) International Publication Date
11 February 2016 (11.02.2016)

- (51) International Patent Classification:
C07K 16/28 (2006.01)
- (21) International Application Number:
PCT/IB2015/055943
- (22) International Filing Date:
5 August 2015 (05.08.2015)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
62/033,177 5 August 2014 (05.08.2014) US
62/053,366 22 September 2014 (22.09.2014) US
62/093,368 17 December 2014 (17.12.2014) US
- (71) Applicant: **MabQuest SA** [CH/CH]; Avenue General-Guisan 62, c/o Giuseppe Pantaleo, 1009 Pully (CH).
- (72) Inventors: **PANTALEO, Giuseppe**; Avenue Général Guisan 62, CH-1009 Pully (CH). **FENWICK, Craig**; Av. Du Léman 36, CH-1005 Lausanne (CH).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,

[Continued on next page]

(54) Title: IMMUNOLOGICAL REAGENTS

FIGURE 2



[Continued on next page]



TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

(57) Abstract: This disclosure relates to binding agents with specificity for programmed cell death 1 (PD-1) and to methods for using the same to treat, prevent and / or ameliorate an infectious disease (e.g., human immunodeficiency virus (HIV)), cancer and / or autoimmunity.